Mayne Pharma (ASX:MYX) completes licensing and supply agreement

[videojs_hls url=’//du7x25at22z7c.cloudfront.net/274492/index_HLSv3.m3u8′ poster=’http://www.finnewsnetwork.com.au/newssystem/Headlines05_360_191113.jpg’]

Mayne Pharma Group Limited (ASX:MYX) is pleased to announce the completion of the licensing and supply agreement for a novel oral contraceptive comprising Estetrol (E4) and drospirenone (E4/DRSP).

Mayne Pharma signed a 20-year exclusive supply and license agreement with Mithra Pharmaceuticals, SA (Mithra) to commercialise E4/DRSP in the United States.

Mayne Pharma CEO, Mr Scott Richards says the drug is expected to transform Mayne Pharma and accelerate the on-going pivot of the company into attractive specialty therapeutic segments in the United States like Women’s Health.

Shares in Mayne Pharma  (ASX:MYX) are trading 2.59 per cent lower at $0.57.
 
Copyright 2019 – Finance News Network

Source: Finance News Network